← Back to Search

Anti-infective Agent

Intermittent infusion (II) group for Infections

Phase 4
Waitlist Available
Led By John Williamson, PharmD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 21
Awards & highlights

Study Summary

This trial is comparing two different treatments to see which is better and safer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 21
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 21 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Nephrotoxicity in Subjects
Secondary outcome measures
Number of Infusion-related Reactions
Number of Leukopenia in Subjects
Number of Participants With Resolutions of Symptoms Associated With the Infection
+2 more

Trial Design

2Treatment groups
Active Control
Group I: Intermittent infusion (II) groupActive Control1 Intervention
Inpatient study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
Group II: continuous infusions (CI) groupActive Control1 Intervention
CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,243 Previous Clinical Trials
1,004,721 Total Patients Enrolled
10 Trials studying Infections
1,497 Patients Enrolled for Infections
John Williamson, PharmDPrincipal InvestigatorWake Forest Health Sciences
1 Previous Clinical Trials
120 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
2021. "Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04648696.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top